The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 24, 2016
Filed:
Dec. 17, 2014
Applicant:
Axikin Pharmaceuticals, Inc., San Diego, CA (US);
Inventors:
Erik Dean Raaum, San Diego, CA (US);
Garrett Thomas Potter, Manchester, GB;
Tai Wei Ly, San Diego, CA (US);
Assignee:
Axikin Pharmaceuticals, Inc., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 31/4523 (2006.01); A61K 31/4427 (2006.01); A61K 31/4155 (2006.01); C07D 413/02 (2006.01); C07D 239/02 (2006.01); C07D 403/02 (2006.01); C07D 401/02 (2006.01); C07D 231/56 (2006.01); C07D 231/02 (2006.01); C07D 413/12 (2006.01); C07D 403/12 (2006.01); C07D 231/38 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 409/14 (2006.01); C07D 417/12 (2006.01); A61K 31/415 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/427 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/69 (2006.01); A61K 45/06 (2006.01); C07D 409/12 (2006.01); C07F 5/02 (2006.01); C07D 401/14 (2006.01); A61K 31/416 (2006.01); A61K 31/4545 (2006.01);
U.S. Cl.
CPC ...
C07D 413/12 (2013.01); A61K 31/415 (2013.01); A61K 31/416 (2013.01); A61K 31/4155 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/427 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/69 (2013.01); A61K 45/06 (2013.01); C07D 231/38 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 417/12 (2013.01); C07F 5/025 (2013.01);
Abstract
Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.